ÌÇÐÄvlog

Object moved to here.

Racial Disparities in Genetic Detection Rates for Inherited Retinal Diseases | Genetics and Genomics | JAMA Ophthalmology | ÌÇÐÄvlog

ÌÇÐÄvlog

[Skip to Navigation]
Sign In
Original Investigation
±·´Ç±¹±ð³¾²ú±ð°ùÌý7, 2024

Racial Disparities in Genetic Detection Rates for Inherited Retinal Diseases

Author Affiliations
  • 1Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan
  • 2Medical Genetics and Ophthalmic Genomics Unit, Ophthalmic Genomics Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland
  • 3Blueprint Genetics Ltd, Helsinki, Finland
  • 4Foundation Fighting Blindness, Columbia, Maryland
  • 5Department of Ophthalmology and Otolaryngology, University of Sao Paulo Medical School, São Paulo, Brazil
  • 6Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan
JAMA Ophthalmol. Published online November 7, 2024. doi:10.1001/jamaophthalmol.2024.4696
Key Points

QuestionÌý What is the association of race on the detection of pathogenic variants via genetic testing for inherited retinal diseases?

FindingsÌý In this 2-group comparison study, Black and White patients with inherited retinal diseases were included. Black patients were less likely to obtain a conclusive genetic diagnosis relative to White patients; older age was also independently associated with decreased genetic diagnosis detection rates.

MeaningÌý In this study, genetic testing for inherited retinal diseases was associated with lower detection rates in Black patients.

Abstract

ImportanceÌý The association of race and detection of pathogenic variants using wide-panel genetic testing for inherited retinal diseases (IRD), to our knowledge, has not been studied previously.

ObjectiveÌý To investigate the genetic detection rates of wide-panel testing in Black and non-Hispanic White patients with IRDs.

Design, Setting, ParticipantsÌý This 2-group comparison used retrospective patient data that were collected at the University of Michigan (UM) and Blueprint Genetics (BG). At UM, inclusion criteria included having a clinical IRD diagnosis, wide-panel genetic testing, and both parents and the patient self-identifying as the same race (Black or non-Hispanic White). Logistic regression analysis was used; the dependent variable was genetic test result (positive or negative/inconclusive) and the independent variables were race, age, sex, phenotype, and number of genes tested. In the BG database, patients with wide-panel testing and self-reported race were included; detection rate comparison analysis based on race was performed using χ2 test of independence. These data were analyzed from October 30, 2013, through October 26, 2022.

Main Outcome and MeasureÌý Genetic test result was considered positive if pathogenic/likely pathogenic variants were detected.

ResultsÌý A total of 572 patients were included in UM, 295 were males (51.6%). Mean age was 45 years. There were 54 Black patients (9.4%) and 518 White patients (90.6%). Black race (odds ratio [OR], 0.25; 95% CI, 0.14-0.46; P < .001) and age (OR per 10 years, 0.84; 95% CI, 0.76-0.92; P < .001) were independently associated with decreased odds of a positive test. In the BG database, 142 of 320 of Black patients (44.4%) had a positive/likely positive test result, a proportion lower than White patients (1691 of 2931 [57.7%]) (χ2 = 18.65; df = 1; P &±ô³Ù; .001).

Conclusions and RelevanceÌý Results from this study highlight a lower genetic detection rate for Black patients than for White patients with IRDs. This supports a concern that the current development of IRD therapeutics is highly dependent on the ability to identify the genetic cause of disease. Patients with no known genetic diagnosis may be disadvantaged in terms of prognostication, inheritance counseling, reproductive decision-making, and eligibility for potential therapeutic options, including clinical trials. As future treatments become available, these findings suggest the need to examine the genetic detection rates across majority and minority subgroups alike.

×